Clinical Efficacy of Flecainide Acetate in Atrial Fibrillation

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Seventy-seven patients with symptomatic atrial fibrillation (AF) received oral flecainide acetate (247 ± 8 mg/day). In 66 patients, previous antiarrhythmic trials consisted of 1–9 drugs. In 55 cases, AF was paroxysmal. It was persistent in 22 patients. Conversion and/or no recurrence of AF was achieved in 40 patients (52%) by flecainide alone and in 11 (14%) by the combination of flecainide and amiodarone. The mean flecainide serum level was 535 ± 46 ng/ml. Age, presence of coronary artery disease or electrocardiographic parameters were not useful for predicting clinical response. In persistent AF, flecainide efficacy decreased with the duration of arrhythmia. Side effects concerned conduction (26%) and congestive heart failure (5%).

Related collections

Author and article information

Journal

Journal ID (publisher-id): CRD

Journal ID (nlm-ta): Cardiology

Journal ID (doi): 10.1159/issn.0008-6312

Title: Cardiology

Publisher: S. Karger AG

ISSN (Print): 0008-6312

ISSN (Electronic): 1421-9751

Publication date Subscription-year: 1990

Publication date (Print): 1990

Publication date (Electronic): 12 November 2008

Volume: 77

Issue: 6

Pages: 443-449

Affiliations

University of Liège, Belgium

Article

Publisher ID: 174636 Other ID: Cardiology 1990;77:443–449

DOI: 10.1159/000174636

PubMed ID: 2127378

SO-VID: b508161e-409a-4344-8b9f-96f81d05d75a

License:

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

History

Date received : 29 November 1989

Date accepted : 23 May 1990

Page count

Pages: 7

Call for Papers: Novel Methods in Vascular and Lymphatic Physiology

Submit here by June 30, 2025

Clinical Efficacy of Flecainide Acetate in Atrial Fibrillation

Read this article at

Abstract

Related collections

Karger: Cardiovascular System

Author and article information

Journal

Affiliations

Article

History

Page count

Categories

Comments

Comment on this article

Similar content 131

Cited by 1